This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
4347 |
4. Check minimum number of events
Min. number of events
3
|
4347 |
5. Include endpointsNone |
4347 |
6. Filter based on genotype QC (FinnGen only) |
3872 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BB Anti-androgens
based on the number of shared cases.
Similar with more cases:
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3872 | - | 3870 |
| Unadjusted period prevalence (%) | 1.77 | - | 1.77 |
| Median age at first event (years) | 72.32 | - | 72.32 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 3997
- Matched controls
- 39970
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L02BB01
ATC
flutamide; oral
57.1
319.6
180
33
N02AA05
ATC
oxycodone; systemic
3.5
313.7
1627
6505
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
234.3
307.7
3886
5195
NK6AN
NOMESCO Finland
Total body bone isotope imaging
13.3
307.7
727
658
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
79.0
307.7
443
63
XX3DW
NOMESCO Finland
Time consuming IT work
4.7
307.7
1024
2722
1523, ,
Kela drug reimbursment
640.6
307.7
816
16
L02AE04
ATC
triptorelin; parenteral
13.6
307.7
439
360
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.6
307.7
2415
7552
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.7
307.7
720
1105
G03HA01
ATC
cyproterone; systemic
17.0
307.7
300
190
L02BB03
ATC
bicalutamide; oral
266.5
307.7
3136
539
Z51.5
ICD-10 Finland
Palliative care
4.3
307.7
1093
3190
WF049
NOMESCO Finland
Radiotherapy of metastasis
13.1
307.7
864
824
ZX112
NOMESCO Finland
Subcutaneous
11.2
307.7
358
349
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
9.2
307.7
640
815
H02AB02
ATC
dexamethasone; systemic
7.2
307.7
1226
2314
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
7.5
307.7
1513
2990
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.5
307.7
819
808
L02BX03
ATC
abiraterone; oral
105.8
307.7
791
93
L02AE03
ATC
goserelin; implant
25.5
307.7
451
198
163
Kela drug reimbursment
Abiraterone and enzalutamide
206.7
307.7
1192
82
WF002
NOMESCO Finland
Radical radiotherapy
4.9
307.7
853
2084
116
Kela drug reimbursment
Prostate cancer
1265.6
307.7
3955
2768
JN4BD
NOMESCO Finland
Extensive body CT
4.4
307.7
1049
3004
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
9.5
307.7
524
624
C61
ICD-10 Finland
Malignant neoplasm of prostate
1043.4
307.7
3973
5473
A03FA01
ATC
metoclopramide; systemic, rectal
4.4
307.7
1473
4684
L02BB04
ATC
enzalutamide; oral
868.9
307.7
1408
25
Y77
ICPC
Malignant neoplasm prostate
23.1
307.7
1723
1268
L02BX02
ATC
degarelix; parenteral
30.9
307.7
732
288
WVA30, ,
SPAT
5.7
307.7
690
1405
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
59.7
307.7
278
50
WF090
NOMESCO Finland
Profylactic radiotherapy
241.2
307.7
578
28
3054, ,
Kela drug reimbursment
638.6
307.7
814
16
XKD00
NOMESCO Finland
Uroflowmetry
3.8
307.7
2154
9353
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
43.2
307.7
477
125
TKE00
NOMESCO Finland
Needle biopsy of prostate
5.6
307.7
937
2060
L02AE02
ATC
leuprorelin; implant, parenteral
29.9
307.7
2421
1953
352
Kela drug reimbursment
Abiraterone and enzalutamide
149.3
307.7
839
71
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
5.7
307.7
1133
2591
ZX090
NOMESCO Finland
Other technic of radiotherapy
9.7
307.7
400
454
M05BX04
ATC
denosumab; parenteral
22.0
307.7
1153
722
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
31.6
307.7
954
393
L03AA13
ATC
pegfilgrastim; parenteral
13.4
307.7
527
448
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
7.7
285.9
423
603
L01XX11
ATC
estramustine; systemic
46.5
280.7
165
37
JN4AD
NOMESCO Finland
Body CT examination
3.7
273.4
1092
3643
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
30.2
270.5
179
62
WZC00
NOMESCO Finland
Treatment plan or consultation
3.1
269.7
1938
9232
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.2
269.3
1683
7400
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
13.7
256.1
243
188
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
7.4
246.9
379
561
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
6.4
227.9
399
677
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
10.7
225.7
251
248
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
61.8
216.2
120
20
WF004
NOMESCO Finland
Palliative radiotherapy
6.9
213.3
346
542
L03AA14
ATC
lipegfilgrastim; parenteral
16.7
211.7
179
112
1CD02, ,
NOMESCO Finland
65.8
209.4
115
18
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
51.5
208.9
120
24
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
6.8
205.3
336
531
L02BB05
ATC
apalutamide; oral
688.7
201.1
197
*
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
21.6
200.5
150
72
XJH00
NOMESCO Finland
Transanal ultrasonography
3.3
200.4
930
3348
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
33.3
196.7
126
39
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
13.3
191.4
184
145
3031
Kela drug reimbursment
Apalutamidi
327.9
184.9
186
6
A04AA01
ATC
ondansetron; systemic, rectal
4.2
184.0
545
1447
1528, ,
Kela drug reimbursment
326.0
183.8
185
6
KFC10
NOMESCO Finland
Bilateral orchiectomy
14.2
179.8
166
122
G04BE03
ATC
sildenafil; oral
6.8
168.9
276
434
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
18.5
167.1
134
75
2BX02, ,
NOMESCO Finland
57.5
160.0
90
16
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
4.7
158.4
396
919
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.0
156.3
485
1326
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
4.7
154.8
385
889
A04AA02
ATC
granisetron; systemic, transdermal
4.2
154.6
452
1183
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
21.7
153.0
114
54
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
6.2
152.8
272
466
A79
ICPC
Malignancy NOS
7.6
150.1
218
301
ZX080
NOMESCO Finland
Image guided radiotherapy
8.2
149.1
203
260
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
6.0
148.2
272
480
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
5.7
145.6
284
531
J01EA01
ATC
trimethoprim; systemic
2.7
145.4
981
4270
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
42.3
144.9
87
21
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
248.9
141.1
144
6
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
13.2
139.6
134
105
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
5.0
134.3
304
648
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
16.0
132.9
114
73
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
7.6
132.6
191
261
XX1XQ
NOMESCO Finland
Other SPECT-CT
232.8
131.7
135
6
ZXC96
NOMESCO Finland
Robot assisted procedure
5.0
130.0
290
610
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
21.8
129.3
96
45
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.3
125.8
262
519
L02BB06
ATC
darolutamide; oral
1214.6
121.5
118
*
U77
ICPC
Malignant neopl urinary tract other
20.2
121.3
93
47
J01MA02
ATC
ciprofloxacin; systemic
2.2
120.8
2103
13579
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
15.1
119.7
106
72
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
211.4
119.3
123
6
UKC02
NOMESCO Finland
Cystoscopy
2.2
118.4
1412
7843
ZX070
NOMESCO Finland
Intensity modified radiotherapy
5.5
115.4
231
441
WF099
NOMESCO Finland
Other radiotherapy
15.1
112.8
100
68
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
17.9
112.2
91
52
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
4.8
111.5
264
583
Y06
ICPC
Prostate symptom/complaint
3.3
110.0
451
1472
Z51.0
ICD-10 Finland
Radiotherapy session
7.1
106.9
164
240
3036, ,
Kela drug reimbursment
+∞
103.6
99
*
1525, ,
Kela drug reimbursment
+∞
103.6
99
*
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
10.9
100.6
109
103
K62.7
ICD-10 Finland
Radiation proctitis
7.5
100.1
146
202
5BX04, ,
NOMESCO Finland
46.0
100.1
59
13
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.0
98.8
1907
12478
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
9.5
98.3
117
126
A06AH03
ATC
naloxegol; oral
6.6
96.9
159
250
R31
ICD-10 Finland
Unspecified haematuria
2.2
89.8
957
4990
R33
ICD-10 Finland
Retention of urine
2.2
83.9
856
4371
ZX112, ,
SPAT
11.6
81.2
84
74
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
8.0
80.1
109
139
1850A
ICD-9 Finland
Malignant neoplasm of prostate[NEOPLASMA MALIGNUM PROSTATAE]
10.7
79.7
87
83
WZC30
NOMESCO Finland
Teaching
2.2
78.5
841
4367
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.1
77.4
934
5073
KEB00
NOMESCO Finland
Biopsy of prostate
4.3
75.3
203
495
TKE10
NOMESCO Finland
Puncture of prostate
6.2
75.3
130
215
G04BE01
ATC
alprostadil; parenteral, urethral
3.5
74.6
272
820
ZX120
NOMESCO Finland
Intravenous
2.5
73.5
522
2268
XX7LT
NOMESCO Finland
Lutetium-177-PSMA treatment
193.6
73.4
76
*
WW500
NOMESCO Finland
Blood transfusion
3.3
72.4
294
948
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
363.8
71.9
72
*
KC1GB
NOMESCO Finland
Cystography with X-ray
5.4
69.0
137
259
OAB42
NOMESCO Finland
Guidance related to known health problem
9.2
65.2
79
87
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
3.8
65.1
204
555
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
15.3
64.0
56
37
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
10.3
60.9
68
67
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.8
59.7
188
513
G04CA02
ATC
tamsulosin; oral
1.7
58.4
2243
17088
L02BX04
ATC
relugolix; oral
11.5
57.8
60
53
ZX050
NOMESCO Finland
Stereotactic radiotherapy
6.1
57.3
100
167
ZXC20
NOMESCO Finland
Use of chemical agents
3.8
56.6
181
499
WVA20, ,
SPAT
3.4
56.4
207
625
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
8.4
55.3
72
87
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.8
53.7
124
267
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.9
51.9
754
4305
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
7.2
50.8
76
108
Z3231
NOMESCO Finland
Registered nurse
1.7
50.8
1216
8068
TKC22
NOMESCO Finland
Catheterisation instruction
3.0
50.6
228
779
TKC20
NOMESCO Finland
Catheterisation of bladder
2.1
49.9
512
2579
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
20.2
49.5
38
19
7512
FHL
Orchidectomy (bilateral)
14.8
49.4
44
30
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
8.5
48.1
62
74
N02BE01
ATC
paracetamol; systemic, rectal
1.9
47.6
3355
29313
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
16.2
46.9
40
25
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
8.6
46.8
60
71
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
14.1
45.9
42
30
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
3.9
45.9
139
369
G04BD12
ATC
mirabegron; oral
1.9
43.8
624
3521
5BA08, ,
NOMESCO Finland
10.1
43.4
49
49
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
7.5
43.2
62
84
XX1AD
NOMESCO Finland
Other CT-examination
6.4
41.4
68
107
KA3EB
NOMESCO Finland
Antegrade pyelography
6.3
41.1
69
111
NK6SN
NOMESCO Finland
Bone SPECT
14.5
39.9
36
25
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
10.1
39.8
45
45
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.3
39.4
101
237
A55
ICPC
General and Unspecified, Local injection/infiltration
5.6
39.2
75
137
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
5.0
38.7
83
168
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
6.0
38.5
68
115
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
11.6
37.8
39
34
N30.4
ICD-10 Finland
Irradiation cystitis
9.9
37.4
43
44
A02BC02
ATC
pantoprazole; systemic
1.6
37.4
2579
21527
Y50
ICPC
Male Genital, Medication/prescr/renewal
10.9
37.3
40
37
1CD04, ,
NOMESCO Finland
370.8
37.1
37
*
Y78
ICPC
Malign neopl male genital other
12.5
36.7
36
29
N39.3
ICD-10 Finland
Stress incontinence
4.1
36.6
103
259
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
3.0
35.7
161
550
A07EA02
ATC
hydrocortisone; rectal
3.6
35.3
118
335
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
7.0
34.7
53
77
TQX05
NOMESCO Finland
Skin puncture, unspecified location
11.8
34.3
35
30
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.1
33.1
70
140
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
9.8
33.0
38
39
G04BD08
ATC
solifenacin; oral
2.1
32.3
331
1655
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.3
32.1
263
1204
SPAT1254
SPAT
Administration of medicine
1.7
29.6
674
4324
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
4.1
29.6
81
200
L03AA02
ATC
filgrastim; parenteral
2.9
28.9
139
493
TKW99
NOMESCO Finland
Other minor surgical procedure in urology
3.9
28.8
86
226
N02AX02
ATC
tramadol; systemic, rectal
1.5
28.5
1701
13466
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
4.0
28.5
82
210
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
3.0
28.3
123
412
SPAT1088
SPAT
Blood transfusion
5.0
28.2
60
121
H02AB06
ATC
prednisolone; systemic
1.4
27.4
1835
14808
-50
ICPC
Medication/prescr/renewal
2.3
27.2
204
898
A28
ICPC
Limited function/disability NOS
1.5
26.8
950
6756
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.7
26.7
567
3564
G04CA52
ATC
tamsulosin and dutasteride; systemic
0.6
26.6
420
6876
KD1GB
NOMESCO Finland
Uretrocystogpaphy with X-ray
7.0
26.3
40
58
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
10.4
26.2
29
28
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
5.3
26.2
53
102
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
4.3
26.0
66
154
D70.82
ICD-10 Finland
Drug-induced neutropenia
3.9
25.6
76
199
KED22
NOMESCO Finland
Transurethral resection of prostate
1.7
25.2
579
3713
U04
ICPC
Incontinence urine
2.0
25.0
269
1368
L02AE01
ATC
buserelin; implant, nasal, parenteral
21.4
24.7
36
17
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
5.6
24.4
46
83
KE1JR
NOMESCO Finland
Extensive PET-CT of prostatic metabolism
48.6
24.3
29
6
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
1.8
24.2
405
2378
KE003
NOMESCO Finland
Adjuvant radiotherapy of prostata and seminal vesicles
29.3
24.1
32
11
B03XA02
ATC
darbepoetin alfa; parenteral
2.6
24.0
140
549
L95
ICPC
Osteoporosis
3.4
23.9
86
257
Z08.8
ICD-10 Finland
Follow-up examination after other treatment for malignant neoplasm
6.4
23.9
39
61
WC205
NOMESCO Finland
Simple therapy of local tumor recidive with hormone
241.4
23.7
24
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.5
23.6
156
650
A06AD11
ATC
lactulose; oral
1.5
23.4
785
5495
TKC52
NOMESCO Finland
Patient education concerning pelvic floor contraction exercises
7.7
22.9
32
42
N35.9
ICD-10 Finland
Urethral stricture, unspecified
2.8
22.5
115
422
J01DB01
ATC
cefalexin; oral
1.4
21.9
2890
25801
G04BE30
ATC
drugs used in erectile dysfunction - combinations
5.5
21.9
42
77
R50.9
ICD-10 Finland
Fever, unspecified
1.6
21.9
644
4371
J01MA12
ATC
levofloxacin; systemic
1.5
21.8
878
6373
Y99
ICPC
Genital disease male other
8.1
21.8
29
36
TPH04
NOMESCO Finland
Cathetrisation of vein
1.5
21.5
917
6728
WX408
NOMESCO Finland
General anesthesy, balanced
1.5
21.4
949
7014
N02AJ06
ATC
codeine and paracetamol; systemic
1.4
20.9
1306
10264
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
7.7
20.8
29
38
KDK10
NOMESCO Finland
Implantation of artificial urinary sphincter around bulbar urethra
7.4
20.8
30
41
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.6
20.8
622
4236
G04BE08
ATC
tadalafil; oral
6.5
20.5
33
51
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
7.8
20.4
28
36
A50
ICPC
General and Unspecified, Medication/prescr/renewal
2.3
20.2
158
709
B01AB05
ATC
enoxaparin; parenteral
1.4
20.0
1182
9187
Z12.5
ICD-10 Finland
Special screening examination for neoplasm of prostate
2.9
19.7
93
327
N02AA03
ATC
hydromorphone; systemic, rectal
6.6
19.6
31
47
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2.1
19.5
198
985
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
24.7
19.5
27
11
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
7.1
19.5
29
41
H02AB07
ATC
prednisone; oral
1.6
19.4
512
3384
XX2RW, ,
NOMESCO Finland
3.4
19.2
70
211
KDG43
NOMESCO Finland
Transobturatorial sling urethrocystopexy
7.2
19.1
28
39
KE1BG
NOMESCO Finland
MRI of prostate
3.0
19.0
82
274
XKG00
NOMESCO Finland
Artificial induction of erection
6.4
18.8
31
49
U08
ICPC
Urinary retention
2.1
18.7
182
891
-55
ICPC
Local injection/infiltration
4.3
18.7
48
113
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.4
18.6
1243
9834
KCV22
NOMESCO Finland
Transluminal endoscopic evacuation of blood clots from bladder
5.5
18.4
35
64
K62.8
ICD-10 Finland
Other specified diseases of anus and rectum
4.0
18.3
51
128
130
Kela drug reimbursment
Malignant tumour
0.5
18.3
181
3440
JN2CM
NOMESCO Finland
Lower part of abdomen extensive MRI examination with Tesla magnet
4.4
18.0
45
104
D64.9
ICD-10 Finland
Anaemia, unspecified
1.5
17.5
615
4321
N47
ICD-10 Finland
Redundant prepuce, phimosis and paraphimosis
1.9
17.1
213
1139
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
5.8
17.1
31
54
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
3.4
17.1
60
177
B01AB10
ATC
tinzaparin; parenteral
1.6
17.0
383
2433
YX9AW, ,
NOMESCO Finland
4.6
16.8
39
85
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
2.5
16.7
104
422
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
4.5
16.6
40
90
SPAT1109
SPAT
Analgesia with portable analgesic pump
3.8
16.5
49
129
R74.9
ICD-10 Finland
Abnormal level of unspecified serum enzyme
3.7
16.2
51
140
KE099
NOMESCO Finland
Other radiotherapy of prostata and seminal vesicles
15.4
16.2
26
17
L02AA02
ATC
polyestradiol phosphate; parenteral
30.1
16.1
21
7
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
2.1
15.8
148
715
S50
ICPC
Skin, Medication/prescr/renewal
3.8
15.5
46
121
B02AA02
ATC
tranexamic acid; systemic
1.7
15.5
272
1617
TQB05
NOMESCO Finland
Puncture of skin of trunk
6.2
15.5
26
42
M01AE01
ATC
ibuprofen; systemic, rectal
1.3
15.3
2839
25821
U07
ICPC
Urine symptom/complaint other
1.7
15.2
305
1879
ECB20
NOMESCO Finland
Oral alveoplasty
3.1
15.2
61
196
R86.9
ICD-10 Finland
Abnormal findings in specimens from male genital organs, unspecified abnormal finding
3.4
15.2
53
156
ZXE20
NOMESCO Finland
More than three and less than five hours
1.5
15.1
570
4057
JN5AN
NOMESCO Finland
Total body isotope imaging
45.2
15.1
18
*
OAA41
NOMESCO Finland
Health check based on individual needs
6.8
14.8
23
34
WC225
NOMESCO Finland
Demanding therapy of local tumor recidive with hormone
56.9
14.8
17
*
G04BE09
ATC
vardenafil; oral
5.5
14.8
28
51
G04BD11
ATC
fesoterodine; oral
2.2
14.7
124
575
U06
ICPC
Haematuria
1.9
14.7
175
923
KDV10
NOMESCO Finland
Internal urethrotomy
2.3
14.7
110
486
M05BA08
ATC
zoledronic acid; parenteral
25.1
14.7
20
8
Z43.5
ICD-10 Finland
Attention to cystostomy
3.0
14.6
63
211
TKD00
NOMESCO Finland
Dilatation of urethra
3.3
14.6
54
165
SPAT1167
SPAT
Insertion of urinary catheter
1.8
14.6
211
1185
U13
ICPC
Bladder symptom/complaint other
2.3
14.5
109
483
NF3AA
NOMESCO Finland
Femur X-ray examination
2.4
14.4
101
434
UKD02
NOMESCO Finland
Urethroscopy
3.6
14.4
46
128
KDE20
NOMESCO Finland
Removal of foreign body from urethra
2.7
14.3
75
280
U28
ICPC
Limited function/disability (U)
2.6
14.2
80
310
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
1.8
13.7
220
1276
J01CA08
ATC
pivmecillinam; oral
1.6
13.5
311
1985
A98
ICPC
Health maint/preventive medicine
1.4
13.1
3202
29878
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.6
13.1
362
2412
KGH10
NOMESCO Finland
Operation for phimosis
1.9
13.0
168
911
NA049
NOMESCO Finland
Radiotherapy of methastasis in spine
19.1
12.9
19
10
SAA03
NOMESCO Finland
Extended examination of mouth
1.3
12.9
981
7839
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
1.6
12.8
324
2116
NE1AA
NOMESCO Finland
Pelvis X-ray examination
1.6
12.7
311
2013
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.4
12.6
724
5539
2AE02, ,
NOMESCO Finland
70.1
12.6
14
*
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
4.8
12.6
28
59
WPA16
NOMESCO Finland
Extensive demanding palliative symptom assessment and treatment
5.5
12.6
24
44
WPB10
NOMESCO Finland
Making a convalescent care decision
4.1
12.5
34
84
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
9.3
12.4
25
27
KEW98
NOMESCO Finland
Other transluminal endoscopic operation on prostate
24.4
12.4
17
7
WPA44, ,
SPAT
4.0
12.2
34
86
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
2.6
11.8
66
255
JN4CD
NOMESCO Finland
Very extensive body CT
1.8
11.7
172
972
C03CA01
ATC
furosemide; systemic
1.3
11.6
1662
14376
C79.1
ICD-10 Finland
Secondary malignant neoplasm of bladder and other and unspecified urinary organs
65.1
11.6
13
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.4
11.5
537
3962
R06AE07
ATC
cetirizine; oral
1.3
11.5
1007
8187
C05AA08
ATC
fluocortolone; rectal, topical
1.5
11.4
434
3085
M05BA02
ATC
clodronic acid; systemic
4.0
11.4
31
77
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
3.0
11.2
47
156
OAB75
NOMESCO Finland
Nutritional guidance related to maintaining health
12.7
11.1
19
15
JN2AE
NOMESCO Finland
Ultrasound examination of lower part of abdomen without contrast
2.8
11.1
53
189
JGA28
NOMESCO Finland
Endoscopic contact coagulation in rectum
5.3
11.1
22
42
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.7
11.0
220
1355
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.3
11.0
81
357
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
0.7
10.9
369
5185
OAB77
NOMESCO Finland
Discussion on exercise habits and instruction concerning use of sports and fitness services
11.9
10.8
19
16
Z51.88
ICD-10 Finland
Other specified medical care
2.2
10.8
87
398
N30.0
ICD-10 Finland
Acute cystitis
1.5
10.8
340
2329
N99.1
ICD-10 Finland
Postprocedural urethral stricture
2.7
10.6
54
199
A04AA55
ATC
palonosetron, combinations; systemic
2.6
10.6
58
222
D630, C61,
ICD-10 Finland
60.2
10.6
12
*
U29
ICPC
Urinary symptom/complaint other
1.9
10.5
127
675
ZXA10
NOMESCO Finland
Bilateral
1.4
10.5
644
4968
ZXE10
NOMESCO Finland
More than one and less than three hours
1.3
10.5
1221
10274
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
5.1
10.3
21
41
U99
ICPC
Urinary disease other
2.8
10.3
51
186
Z2221
NOMESCO Finland
Medical doctor
1.3
10.3
851
6852
WPA44
NOMESCO Finland
Nursing home for palliative care
4.9
10.2
22
45
R39.1
ICD-10 Finland
Other difficulties with micturition
1.7
10.1
173
1022
M04AA01
ATC
allopurinol; systemic
0.7
10.1
476
6325
AA1BD
NOMESCO Finland
Extensive CT of head and brain
2.0
10.1
100
496
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.2
10.0
1511
13088
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
2.1
10.0
91
438
WPA45
NOMESCO Finland
Continuous drug infusion in palliative care
5.1
9.8
20
39
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
3.3
9.7
36
111
SPAT1255
SPAT
Intravenous administration of medicine
1.5
9.6
272
1822
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
2.3
9.4
67
291
XX9AW
NOMESCO Finland
Production of copy from X-ray picture
2.2
9.4
80
375
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
2.5
9.3
56
226
L28
ICPC
Limited function/disability (L)
1.3
9.3
751
6020
D40.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Male genital organ, unspecified
4.4
9.1
22
50
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
4.4
9.1
22
50
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
4.6
9.1
21
46
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
3.2
9.0
35
111
NE049
NOMESCO Finland
Radiotherapy of methastasis in pelvis, sacrum or coggyx
36.8
9.0
11
*
TQX20
NOMESCO Finland
Implantation of subcutaneous medicament implant
7.0
9.0
21
30
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
1.9
9.0
116
632
I25.1
ICD-10 Finland
Atherosclerotic heart disease
0.8
8.9
1050
12364
G04CB01
ATC
finasteride; oral
0.8
8.9
675
8387
EB1WA, ,
NOMESCO Finland
3.6
8.8
28
78
U50
ICPC
Urological, Medication/prescr/renewal
10.7
8.8
16
15
Z08.2
ICD-10 Finland
Follow-up examination after chemotherapy for malignant neoplasm
10.7
8.8
16
15
KC1AT
NOMESCO Finland
Puncture of urinary bladder with ultrasound guidance
4.1
8.7
23
56
A21
ICPC
Risk factor for malignancy
7.6
8.6
19
25
KEC10
NOMESCO Finland
Perineal radical prostatectomy
11.6
8.6
15
13
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
1.4
8.6
403
2975
ZXD10
NOMESCO Finland
Scheduled procedure
1.2
8.6
1258
10816
I89.0
ICD-10 Finland
Lymphoedema, not elsewhere classified
3.6
8.5
27
75
G04CB02
ATC
dutasteride; oral
0.7
8.5
379
5091
7461
FHL
Needle biopsy in the operating room
3.2
8.5
33
105
SAA02
NOMESCO Finland
Basic examination of mouth
1.2
8.5
1653
14633
A29
ICPC
General symptom/complaint other
1.4
8.5
476
3617
U05
ICPC
Urination problems other
1.5
8.4
244
1642
D07.5
ICD-10 Finland
Carcinoma in situ: Prostate
7.3
8.4
19
26
N30.9
ICD-10 Finland
Cystitis, unspecified
1.7
8.4
155
937
L02AB02
ATC
medroxyprogesterone; systemic
8.5
8.3
17
20
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
4.1
8.2
22
54
WB221
NOMESCO Finland
Demanding neoadjuvant hormone therapy of malignancy
3.8
8.2
24
63
WX110
NOMESCO Finland
Infiltration anesthesia
1.2
8.2
2102
19090
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
3.2
8.2
31
97
YN7VG
NOMESCO Finland
MRI examination of spine with high intesinty magnet for dose design of radiotherapy
33.4
8.1
10
*
N05CF01
ATC
zopiclone; oral
1.2
8.0
1110
9468
WPA41, ,
SPAT
22.1
8.0
11
5
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
2.2
8.0
66
307
Z46.6
ICD-10 Finland
Fitting and adjustment of urinary device
4.3
7.9
20
47
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
1.7
7.9
148
899
ZX100
NOMESCO Finland
Oral
2.2
7.9
64
295
7455
FHL
Retropubic total prostatectomy
9.4
7.8
15
16
Y26
ICPC
Fear of genital cancer male
9.4
7.8
15
16
J01MA06
ATC
norfloxacin; oral
1.4
7.8
308
2207
A10BK03
ATC
empagliflozin; oral
0.7
7.7
207
3053
N21.0
ICD-10 Finland
Calculus in bladder
2.1
7.6
73
359
J01MA01
ATC
ofloxacin; systemic
1.4
7.6
341
2495
Y55
ICPC
Male Genital, Local injection/infiltration
25.0
7.6
10
*
WPA11
NOMESCO Finland
Developing a plan for palliative care
4.1
7.5
20
49
JR2PR, ,
NOMESCO Finland
80.2
7.4
8
*
F03
ICD-10 Finland
Unspecified dementia
0.6
7.4
98
1709
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.2
7.4
1923
17418
EBA10
NOMESCO Finland
Operative extraction of tooth
1.5
7.4
254
1773
A10BB01
ATC
glibenclamide; oral
0.6
7.4
106
1806
KDW96
NOMESCO Finland
Other operations on urethra
4.0
7.3
20
50
8010/3-C61.9
ICD-O-3
Carcinoma, NOS, of prostate gland
10.9
7.3
13
12
I21.9
ICD-10 Finland
Acute myocardial infarction, unspecified
0.4
7.2
30
789
A07DA03
ATC
loperamide; oral
1.7
7.1
127
762
TQW40
NOMESCO Finland
Remowal of suture of skin
1.5
7.1
199
1333
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
0.8
7.0
963
11220
XKD11, ,
NOMESCO Finland
10.0
7.0
13
13
KC1AE
NOMESCO Finland
Percutaneous ultrasound examination of urinary bladder
3.6
7.0
22
61
B01AE07
ATC
dabigatran etexilate; oral
1.6
7.0
169
1096
Z93.6
ICD-10 Finland
Other artificial openings of urinary tract status
6.3
6.9
17
27
L02BA01
ATC
tamoxifen; oral
5.8
6.9
18
31
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
0.7
6.9
338
4476
WPA43, ,
SPAT
3.8
6.8
20
53
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
0.8
6.8
412
5292
K02.1
ICD-10 Finland
Caries of dentine
1.2
6.8
1506
13411
XX9CN, ,
NOMESCO Finland
40.1
6.8
8
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
2.4
6.7
42
173
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
0.6
6.7
130
2058
WPA40
NOMESCO Finland
Individual-centered psychosocial intervention in palliative care
16.7
6.7
10
6
R11
ICD-10 Finland
Nausea and vomiting
1.5
6.7
219
1516
ZX022
NOMESCO Finland
LDR radiotherapy within tissue
5.5
6.6
18
33
JN2BD
NOMESCO Finland
Extensive CT exmaniation of lower part of abdomen
5.5
6.6
18
33
SPAT1262
SPAT
Handing over of treatment supplies
1.3
6.6
705
5829
G04CA01
ATC
alfuzosin; oral
1.2
6.5
891
7569
M907, C61,
ICD-10 Finland
70.0
6.4
7
*
R4110
NOMESCO Finland
Physiotherapy
1.2
6.4
877
7452
A41.8
ICD-10 Finland
Other specified sepsis
1.8
6.3
95
544
KH1RT
NOMESCO Finland
Urinary tract dilatatation with radiological guidance
11.0
6.3
11
10
Z50.1
ICD-10 Finland
Other physical therapy
1.5
6.3
161
1058
G04BD07
ATC
tolterodine; oral
1.6
6.3
154
1002
JFA45
NOMESCO Finland
Endoscopic contact coagulation in colon
2.6
6.3
35
137
L01XK01
ATC
olaparib; oral
+∞
6.2
6
*
C61, C798,
ICD-10 Finland
+∞
6.2
6
*
WW500, ,
SPAT
7.0
6.2
14
20
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
0.8
6.2
858
10008
N05AD01
ATC
haloperidol; systemic
1.6
6.2
131
824
ZX114
NOMESCO Finland
Intramuscular
2.5
6.2
37
150
WX402
NOMESCO Finland
General anaesthesia
1.3
6.1
577
4697
HAC20
NOMESCO Finland
Total mastectomy
5.7
6.1
16
28
103
Kela drug reimbursment
Diabetes, insulin-treated
0.8
6.1
906
10504
U79
ICPC
Neoplasm urinary tract unspecified
7.7
6.1
13
17
SPAT1245
SPAT
Provision of support and information to patient’s family members
1.5
6.1
207
1442
201
Kela drug reimbursment
Chronic cardiac insufficiency
0.7
6.0
166
2432
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1884
3906
8.23
307.65
2.9
2.1
4.13
13.33
nmol/l
265.70
1552
3386
1995
11355
2.51
173.88
9.0
3.4
2.34
2.33
mmol/l
4.88
1900
10148
2672
18436
2.36
137.10
14.8
6.7
10.76
13.80
umol/l
38.92
2621
17633
3195
24869
2.42
108.54
19.7
8.7
93.65
83.40
u/l
10.63
3143
23544
2553
18416
2.07
101.47
11.9
8.0
1.21
1.20
mmol/l
6.59
2258
15775
3210
25336
2.36
100.49
20.7
5.8
25.91
3.06
ug/l
19.39
3071
22520
1962
13095
1.98
94.64
4.7
3.9
198.34
121.48
e6/l
0.54
1698
10470
2719
20358
2.05
93.70
10.9
4.9
19.42
22.50
%
18.64
1982
11210
2860
21817
2.09
93.54
6.3
5.0
230.48
807.43
e6/l
1.08
77
423
2009
13828
1.91
85.28
5.4
4.5
139.24
109.36
e6/l
0.62
1717
10655
2102
14706
1.91
84.63
5.8
3.5
1.62
0.81
ug/l
22.16
1666
10788
2482
18369
1.93
83.68
16.2
8.9
4.23
4.62
e9/l
12.85
2205
15724
1483
9441
1.91
78.03
3.3
3.0
2.74
2.83
e6/l
0.25
1384
8633
1680
11219
1.86
75.43
4.5
3.8
0.38
0.48
e6/l
1.09
1444
8684
2238
16609
1.79
68.38
9.4
7.3
1.21
1.20
mmol/l
10.35
2163
15244
1153
7125
1.87
63.88
5.1
3.3
2.47
2.45
mmol/l
3.52
1066
6293
1059
6517
1.85
58.60
4.2
3.7
0.77
0.71
e6/l
0.32
679
3612
957
5706
1.89
58.50
6.3
4.1
268.38
245.16
u/l
2.64
919
5366
2170
16559
1.68
54.56
6.3
5.6
33.96
34.07
g/l
0.36
2061
15392
1425
10088
1.64
45.40
5.0
3.3
33.70
39.17
u/l
1.55
1368
9430
1059
6960
1.71
44.76
4.1
3.5
0.87
0.92
e6/l
0.26
689
4054
1961
15694
1.49
32.61
3.6
3.2
—
—
estimate
—
0
0
604
3707
1.74
31.43
3.5
2.8
0.42
0.45
e6/l
0.20
584
3610
2623
22517
1.48
28.88
38.3
27.4
14.16
14.04
%
3.79
2600
22189
3228
29003
1.59
28.16
27.9
22.4
35.74
31.77
mg/l
7.30
2954
25335
2331
19645
1.45
27.60
17.1
22.7
1.32
1.43
inr
14.89
1989
16868
1917
15696
1.43
25.87
6.2
6.4
22.90
24.26
%
5.75
1826
14761
1716
13817
1.42
25.20
17.6
13.5
0.01
0.00
e9/l
0.66
1406
11189
2479
21362
1.42
24.42
5.3
5.9
6.96
7.03
mmol/l
0.70
2406
20508
486
3000
1.71
24.38
6.6
4.4
1.21
1.21
mmol/l
0.78
449
2597
1861
15356
1.40
22.98
6.1
6.2
61.18
59.81
%
4.76
1776
14565
3288
30270
1.49
19.61
31.5
27.8
139.26
139.57
mmol/l
10.00
3245
29632
3290
30297
1.49
19.54
32.0
28.0
4.02
4.05
mmol/l
6.99
3245
29635
3303
30519
1.47
18.52
42.6
30.0
92.52
96.00
umol/l
5.76
3266
30022
1358
10916
1.37
18.40
2.1
2.5
2.88
2.94
mg/l
0.50
1161
9313
984
7505
1.41
18.26
2.5
2.9
12.07
12.06
umol/l
0.02
924
6938
3306
30573
1.47
18.25
45.2
33.2
6.77
7.22
e9/l
19.36
3247
29615
3305
30566
1.47
18.20
45.6
33.8
37.59
39.94
%
101.20
3270
30040
3305
30566
1.47
18.20
45.1
33.1
4.15
4.41
e12/l
133.43
3242
29605
3305
30566
1.47
18.20
45.0
33.0
92.50
92.24
fl
2.71
3274
30066
3305
30569
1.47
18.16
45.5
33.4
125.34
134.11
g/l
159.95
3273
30077
3304
30564
1.47
18.09
45.3
33.2
228.81
224.07
e9/l
4.04
3252
29731
1988
16973
1.34
18.00
4.5
4.0
0.02
0.10
estimate
0.47
480
3505
1957
16679
1.34
17.89
4.5
4.0
0.00
0.00
estimate
1.08
502
3793
861
11219
0.70
17.85
2.0
2.0
1.40
1.27
mmol/l
4.86
695
9057
3241
29904
1.44
17.69
20.9
13.5
22.27
26.58
u/l
20.98
3175
28729
1974
16900
1.33
17.24
4.5
4.0
2.38
3.73
estimate
0.21
516
3852
3013
27496
1.39
17.10
33.6
22.3
72.66
70.61
ml/min/173m2
7.11
2902
25849
930
7102
1.40
16.94
2.3
2.9
2.12
2.18
g/l
3.36
867
6517
1975
16936
1.33
16.93
6.3
6.0
1.59
1.82
e9/l
4.05
1703
14618
1112
8813
1.36
15.99
5.0
4.7
85.17
77.50
%
19.20
1095
8648
1070
8433
1.37
15.93
4.1
3.7
0.04
0.22
estimate
0.85
361
2880
1984
17120
1.32
15.83
6.4
6.1
0.19
0.21
e9/l
7.18
1680
14668
1078
13290
0.74
15.09
3.2
3.6
7.49
7.95
mmol/l
3.54
869
10971
867
6663
1.38
14.95
2.3
2.9
22.45
22.19
%
0.23
813
6155
1075
13217
0.74
14.64
3.2
3.7
49.15
61.40
mg/l
1.38
757
9374
313
1962
1.65
14.61
4.2
3.6
1.02
1.02
ratio
0.71
294
1792
1484
12415
1.31
14.37
4.7
4.1
0.04
0.10
estimate
0.34
421
3186
1920
16644
1.30
14.17
6.1
5.9
0.62
0.67
e9/l
9.77
1594
14027
987
7803
1.35
14.12
2.0
2.0
—
—
—
0
0
348
2265
1.59
13.92
1.8
1.9
3.43
2.32
ug/l
0.44
310
1968
1925
16732
1.29
13.75
6.1
5.9
0.03
0.04
e9/l
12.44
1595
14126
2444
22030
1.28
12.54
40.4
29.2
331.14
332.37
g/l
9.31
2430
21846
1133
13620
0.77
12.53
4.0
4.4
8.83
10.25
mg/mmol
0.69
765
9266
985
7935
1.32
12.10
3.5
3.1
0.17
0.07
0.65
35
286
831
6643
1.32
10.59
3.1
3.3
0.82
0.82
mmol/l
0.63
800
6237
1070
8848
1.29
10.57
3.3
2.8
—
—
—
0
0
1594
13854
1.25
10.31
2.8
3.3
375.02
187.88
ug/l
17.33
1459
12559
739
5849
1.32
10.06
2.0
1.9
—
—
—
0
0
684
5405
1.32
9.36
2.0
1.9
—
—
—
0
0
573
4416
1.35
9.31
3.4
4.3
22.40
31.71
ug/l
0.45
472
3752
405
2987
1.40
8.64
1.5
1.7
—
—
—
0
0
309
4298
0.70
8.50
10.2
9.0
—
—
—
0
0
96
507
1.92
8.19
1.9
1.2
—
—
—
0
0
171
1070
1.62
8.12
3.4
3.7
1.61
1.79
index
0.20
88
599
1955
17780
1.19
7.06
3.6
3.5
59.80
63.64
u/l
0.70
1822
16239
369
4823
0.74
6.86
1.2
1.2
1.77
1.97
u/ml
0.15
78
1177
1150
9979
1.21
6.83
4.6
4.1
0.00
0.00
estimate
0.38
422
3219
577
4657
1.28
6.60
3.4
4.0
1.44
1.61
mmol/l
0.43
472
3973
589
4770
1.28
6.56
3.3
4.0
5.63
5.81
kpa
3.84
579
4628
198
1355
1.49
6.38
1.2
1.3
—
—
—
0
0
325
4255
0.74
6.09
4.5
5.5
31.19
32.90
%
1.96
211
2765
63
321
1.98
6.06
2.2
1.1
173.74
66.62
u/l
2.51
54
279
277
3712
0.73
6.06
1.2
1.3
10.85
14.36
u/ml
0.32
82
1253
907
7776
1.22
5.98
3.9
4.7
1241.77
521.76
ng/l
0.36
810
7046
880
10188
0.83
5.81
2.9
3.4
372.41
379.74
umol/l
1.10
734
8746
510
4126
1.27
5.70
3.2
2.9
7.66
11.06
umol/l
2.60
463
3693
124
796
1.58
5.42
2.4
3.9
2.50
1.51
%
2.13
105
696
178
2515
0.69
5.35
1.6
1.4
—
—
—
0
0
1461
13173
1.17
5.34
2.3
2.2
—
—
—
0
0
1878
20302
0.86
5.32
3.2
3.4
15.09
15.08
pmol/l
0.08
1682
17929
1559
14144
1.17
5.24
3.4
3.6
2106.54
2108.65
ng/l
0.01
1429
12552
483
3941
1.26
5.02
2.8
3.3
4.24
4.44
kpa
1.27
467
3812
481
3923
1.26
5.02
3.0
3.3
230.04
274.77
ng/l
1.55
453
3646
39
181
2.17
4.87
2.3
1.5
3.13
7.79
u/l
2.91
31
142
370
4603
0.78
4.72
1.3
1.6
2.83
2.98
g/l
0.49
217
2729
1240
11172
1.16
4.38
2.7
2.8
54.89
68.78
u/l
1.23
1178
10382
42
210
2.01
4.36
1.8
3.4
1.77
1.21
%
1.02
42
210
307
2414
1.29
4.33
1.6
1.5
—
—
—
0
0
857
7512
1.18
4.28
4.9
4.3
1.02
1.02
kg/l
0.74
674
5249
360
2901
1.26
4.18
1.9
1.8
—
—
—
0
0
60
1009
0.59
4.11
1.3
1.5
8.28
7.08
iu/ml
0.06
11
237
37
181
2.05
4.09
1.3
1.1
73.00
103.49
u/l
1.38
30
160
323
4006
0.79
4.02
1.2
1.3
33.24
42.61
iu/ml
0.56
107
1104
201
2643
0.75
3.92
1.7
1.7
1.64
1.71
%
0.37
167
2141
36
178
2.03
3.88
1.3
1.1
35.54
35.20
u/l
0.01
28
157
141
1935
0.72
3.66
2.9
2.7
—
—
—
0
0
151
1099
1.39
3.63
1.3
1.6
—
—
—
0
0
36
183
1.98
3.62
2.7
1.2
89.48
116.65
u/l
0.60
29
148
381
3159
1.23
3.46
2.3
2.6
31.21
40.20
u/l
2.71
307
2671
280
2243
1.27
3.46
3.6
3.7
25.05
24.88
mmol/l
0.28
273
2162
105
723
1.46
3.44
2.4
2.2
32.12
32.89
pg
1.08
105
718
21
454
0.46
3.30
1.1
1.1
—
—
—
0
0
49
815
0.60
3.29
1.5
1.7
12.13
13.16
mg/l
0.32
43
746
867
7788
1.14
3.05
4.4
3.7
0.08
0.26
0.84
12
98
33
174
1.90
3.04
2.9
1.2
24.88
33.04
u/l
0.61
26
141
55
855
0.64
2.82
1.5
1.5
0.21
16.24
iu/ml
1.27
13
210
1259
11636
1.12
2.78
1.9
1.8
17.32
18.86
nmol/l
3.83
1103
9884
126
937
1.36
2.74
1.5
1.4
—
—
—
0
0
126
937
1.36
2.74
1.5
1.4
—
—
—
0
0
1606
15058
1.11
2.71
4.5
4.8
75.42
84.20
ng/l
0.14
1383
12598
648
5756
1.15
2.67
4.7
6.7
1.03
1.04
mmol/l
0.40
603
5382
37
618
0.59
2.60
2.4
1.3
8.59
8.20
u/l
0.08
19
495
96
1316
0.72
2.57
1.5
1.6
38.17
36.94
u/l
0.21
81
1096
343
2907
1.20
2.54
3.2
3.5
119.38
127.94
g/l
9.33
334
2816
244
2002
1.23
2.52
4.0
5.3
0.85
0.85
%
0.09
232
1895
198
2443
0.80
2.43
2.2
2.7
10.07
10.92
g/l
1.97
178
2243
9
224
0.40
2.41
1.1
1.1
—
—
—
0
0
17
348
0.49
2.38
1.1
1.1
—
4.36
—
0
11
43
266
1.62
2.37
2.7
2.8
44.35
36.45
mg/l
0.52
37
214
31
528
0.58
2.37
1.2
1.3
—
—
—
0
0
262
2183
1.21
2.35
3.9
5.1
1.49
1.60
%
1.99
249
2071
78
1087
0.71
2.33
1.3
1.6
0.34
0.31
mg/l
0.15
39
508
55
815
0.67
2.31
1.2
1.2
—
230.00
—
0
22
143
1115
1.29
2.29
1.3
1.6
—
—
—
0
0
524
4642
1.15
2.26
5.2
7.3
11.72
12.11
mmol/l
0.54
497
4404
40
630
0.63
2.24
1.2
1.2
4.93
3.45
u/ml
—
9
71
6
167
0.36
2.13
2.3
1.8
303.33
329.43
mu/l
—
6
125
57
824
0.69
2.13
1.7
1.8
115.20
197.02
pmol/l
5.29
45
758
733
6666
1.12
2.10
1.6
1.7
2.35
1.74
mg/l
1.98
596
5350
76
1040
0.73
2.07
1.0
1.1
—
1.63
—
0
12
78
566
1.39
2.05
1.4
1.5
—
—
—
0
0
2516
25977
0.92
1.98
4.0
4.5
2.20
2.10
mu/l
0.72
2252
23154
80
1075
0.74
1.96
3.1
3.1
0.86
0.83
nmol/l
0.26
64
846
218
1821
1.21
1.95
1.9
2.1
—
—
—
0
0
23
399
0.57
1.94
1.0
1.2
1.56
1.49
nmol/l
0.13
18
357
301
2591
1.17
1.93
1.4
1.7
1.76
1.53
g/l
3.04
260
2211
282
2415
1.18
1.92
2.2
2.8
1.13
1.16
%
0.24
277
2406
279
2389
1.18
1.90
2.2
2.7
0.64
0.63
%
0.29
274
2382
86
1136
0.75
1.88
2.5
2.6
1.99
1.91
mg/l
0.30
76
989
74
543
1.37
1.85
1.6
2.0
86.54
88.63
%
1.21
74
537
157
1920
0.81
1.84
1.4
2.0
0.95
1.42
g/l
4.65
137
1730
142
1143
1.25
1.82
2.1
2.5
117.08
128.82
g/l
6.19
115
886
13
262
0.49
1.81
1.0
1.1
—
15.02
—
0
29
52
360
1.45
1.81
1.7
1.9
2.79
1.15
u/field
0.79
28
202
25
145
1.73
1.81
2.8
2.3
5.03
4.86
kpa
0.19
25
145
71
520
1.37
1.80
2.3
3.9
62.85
59.14
%
0.71
54
433
58
806
0.72
1.78
1.2
1.4
0.25
0.24
g/l
0.41
53
772
88
668
1.32
1.78
1.3
1.3
—
—
—
0
0
34
523
0.65
1.78
1.0
1.1
—
2.43
—
0
26
43
628
0.68
1.75
1.4
1.3
—
—
—
0
0
24
398
0.60
1.74
1.5
1.3
105406.00
144160.30
e6/l
0.15
15
271
56
397
1.42
1.73
2.8
1.5
43.62
32.29
ng/l
0.38
56
397
9
194
0.46
1.72
1.1
1.1
—
—
—
0
0
109
1369
0.79
1.66
1.4
1.3
476.66
343.41
u/ml
0.40
101
1248
45
643
0.70
1.64
1.2
1.2
—
39.34
—
0
16
466
4191
1.13
1.64
4.0
4.1
—
—
—
0
0
79
1028
0.76
1.60
1.6
2.4
32.03
33.84
umol/l
0.31
70
904
74
967
0.76
1.55
1.4
1.5
18989.26
17776.63
e6/l
0.09
47
674
140
1695
0.82
1.54
2.4
2.5
30.89
16.83
au/ml
—
10
108
86
1100
0.78
1.54
1.3
1.4
—
—
—
0
0
199
1691
1.19
1.54
1.8
1.9
—
—
—
0
0
24
145
1.66
1.54
2.9
2.3
9.42
10.01
kpa
0.50
24
145
42
290
1.45
1.52
1.2
1.5
—
—
—
0
0
14
258
0.54
1.52
1.1
1.1
—
1.64
—
0
16
272
3107
0.87
1.51
7.6
9.6
93.73
93.75
%
0.02
272
3093
376
4198
0.88
1.49
2.5
2.5
6.79
7.21
ug/l
0.14
334
3656
85
662
1.29
1.48
5.5
6.4
13.24
12.03
mg/l
1.39
80
607
74
959
0.77
1.47
1.5
1.5
29.96
31.08
g/l
0.39
63
853
326
2893
1.14
1.44
4.7
2.9
62.51
58.86
ml/min/173m2
1.04
156
1277
5
16
3.13
1.44
1.4
1.1
6.14
6.32
mmol/l
—
5
16
98
781
1.26
1.43
1.4
1.7
—
—
—
0
0
13
66
1.97
1.43
1.3
1.4
730.00
418.48
nmol/24h
0.23
13
66
102
817
1.25
1.43
4.1
3.8
29.04
33.97
mg/l
0.94
85
591
37
529
0.70
1.40
1.6
1.6
6.47
4.84
mg/l
0.36
29
395
9
179
0.50
1.39
1.1
1.1
—
—
—
0
0
129
1553
0.83
1.37
1.2
1.3
89.40
64.01
au/ml
—
8
117
18
299
0.60
1.37
1.0
1.0
309.45
320.06
ng/l
0.07
11
195
18
299
0.60
1.37
1.0
1.0
34.72
42.29
ng/l
0.34
11
188
18
299
0.60
1.37
1.0
1.0
908.90
648.94
ng/l
—
10
190
118
967
1.23
1.36
3.4
5.1
2.25
2.53
mmol/l
0.61
70
653
146
1729
0.84
1.31
3.0
4.3
24.25
24.65
mmol/l
0.95
126
1564
40
284
1.41
1.29
1.2
1.5
—
—
—
0
0
5
116
0.43
1.25
1.0
1.3
191.20
187.21
mmol/24h
—
5
116
13
227
0.57
1.21
1.1
1.3
323.99
390.01
ug/l
—
7
107
9
168
0.53
1.18
1.1
1.1
—
—
—
0
0
9
168
0.53
1.18
1.1
1.1
—
—
—
0
0
48
358
1.34
1.18
1.4
1.5
—
—
—
0
0
42
308
1.37
1.15
1.3
1.4
—
—
—
0
0
2771
28260
0.94
1.15
5.6
6.5
2.50
2.31
mmol/l
22.83
2478
25609
12
209
0.57
1.13
2.3
2.3
195.08
250.14
e6/l
0.80
12
191
32
225
1.43
1.12
1.0
1.3
—
—
—
0
0
32
225
1.43
1.12
1.0
1.3
—
—
—
0
0
48
627
0.76
1.08
1.3
1.4
562.62
1203.02
e6/l
0.62
37
501
9
164
0.55
1.08
1.1
1.1
—
—
—
0
0
134
1142
1.18
1.08
2.7
3.2
87.67
88.34
%
0.45
128
1108
52
669
0.77
1.05
1.1
1.1
—
—
—
0
0
48
621
0.77
1.02
1.2
1.3
6.28
30.77
e6/l
1.35
32
465
31
427
0.72
1.01
2.6
2.4
982.97
1093.46
mg
0.14
31
421
523
4866
1.09
1.00
2.9
2.5
64.74
66.39
e9/l
0.61
396
3706
113
958
1.18
0.99
1.3
1.4
—
—
—
0
0
53
673
0.78
0.98
1.4
1.3
—
—
—
0
0
234
2610
0.89
0.98
2.0
2.3
175.72
185.76
ug/g
0.11
187
2074
9
160
0.56
0.98
1.1
1.1
—
—
—
0
0
0
29
0.00
0.97
0.0
4.0
—
—
—
0
0
0
29
0.00
0.97
0.0
1.1
—
—
—
0
0
0
30
0.00
0.97
0.0
1.0
—
—
—
0
0
718
6775
1.07
0.96
2.3
2.0
29.99
30.42
s
1.13
697
6598
11
62
1.78
0.94
1.0
1.2
—
—
—
0
0
6
29
2.07
0.89
1.2
1.2
16.33
11.83
u/l
—
6
29
5
103
0.48
0.89
2.2
2.8
15.48
14.70
ml/dl
—
5
97
9
153
0.59
0.88
1.0
1.1
—
—
—
0
0
9
155
0.58
0.88
1.1
1.1
—
—
—
0
0
276
3017
0.91
0.83
7.5
9.7
0.59
0.62
%
0.77
271
2993
21
296
0.71
0.82
3.1
3.6
—
—
—
0
0
2707
27514
0.95
0.81
4.9
5.6
4.35
4.06
mmol/l
38.18
2430
25050
2683
27275
0.95
0.81
4.8
5.5
1.35
1.30
mmol/l
9.67
2390
24590
71
850
0.83
0.81
1.5
1.6
37.36
35.08
u/ml
0.08
16
146
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
0
27
0.00
0.77
0.0
14.7
—
278.14
—
0
21
1317
12741
1.05
0.77
2.1
2.2
83.27
76.90
nmol/l
11.88
1178
11015
28
209
1.34
0.75
2.0
1.8
3.80
2.24
u/field
0.53
20
140
58
700
0.83
0.73
1.8
1.9
3.51
3.13
mmol/l
1.44
42
530
56
676
0.83
0.71
1.1
1.3
0.89
0.84
nmol/l
0.21
45
560
46
371
1.24
0.71
3.2
3.6
11.13
11.63
index
0.25
31
211
142
1593
0.89
0.71
2.6
4.1
1.53
1.50
mmol/l
0.10
136
1570
19
263
0.72
0.69
2.4
2.1
99.00
201.83
ug/min
—
10
71
9
145
0.62
0.69
1.1
1.2
—
61.00
%
—
0
20
175
1581
1.11
0.68
3.2
3.6
192.31
3599.86
u/ml
1.25
150
1372
23
307
0.75
0.67
1.2
1.3
—
174.67
—
0
30
5
92
0.54
0.67
1.0
1.1
1115.40
1472.53
miu/ml
—
5
92
441
4155
1.07
0.66
3.1
2.6
65.39
65.69
g/l
0.36
400
3745
69
586
1.18
0.66
1.4
1.5
—
—
—
0
0
27
206
1.31
0.65
1.1
1.9
—
—
—
0
0
27
206
1.31
0.65
1.1
1.9
—
—
—
0
0
27
206
1.31
0.65
1.1
1.9
—
—
—
0
0
27
206
1.31
0.65
1.1
1.9
—
—
—
0
0
15
103
1.46
0.65
6.5
7.2
105.39
258.00
ug/l
—
10
78
442
4169
1.07
0.64
5.6
7.5
1.31
1.42
mmol/l
1.85
430
4059
101
1148
0.88
0.64
2.0
2.3
190.50
110.49
ug/min
0.58
58
664
18
247
0.73
0.64
1.1
1.2
60.00
100.83
titre
—
6
36
18
247
0.73
0.64
1.1
1.2
—
126.67
—
0
9
119
1058
1.13
0.62
2.0
2.1
4.01
3.67
g/l
1.30
112
1000
20
147
1.36
0.61
1.3
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
208
1911
1.09
0.60
2.5
2.6
0.31
0.33
iu/ml
0.36
105
1042
27
345
0.78
0.60
1.3
1.3
—
—
—
0
0
84
733
1.15
0.59
2.1
5.0
169.88
3712.32
iu/ml
—
8
114
82
938
0.87
0.59
1.1
1.1
105.27
90.86
u/ml
0.11
27
267
0
23
0.00
0.58
0.0
2.1
—
—
—
0
0
8
53
1.51
0.58
1.0
1.1
—
—
—
0
0
34
420
0.81
0.57
1.5
1.5
—
—
—
0
0
8
54
1.48
0.57
1.0
1.4
—
4941.25
—
0
8
25
319
0.78
0.56
1.6
1.3
—
—
—
0
0
107
954
1.12
0.56
4.4
6.8
104.19
105.26
mmol/l
1.46
97
857
107
954
1.12
0.56
4.4
6.8
11.40
11.44
mmol/l
0.04
97
857
6
38
1.58
0.54
1.0
1.1
—
—
—
0
0
156
1707
0.91
0.54
2.3
3.2
2.00
4.75
ratio
0.79
97
1016
9
61
1.48
0.53
1.3
1.1
—
—
—
0
0
2598
26311
0.96
0.52
4.1
4.8
1.33
1.25
mmol/l
7.19
2277
23470
14
100
1.40
0.51
1.8
2.7
406.93
363.79
ug/l
0.03
14
100
95
847
1.12
0.51
1.2
1.4
—
—
—
0
0
161
1751
0.92
0.50
2.1
2.5
1.03
1.21
g/l
0.23
134
1478
175
1896
0.92
0.50
2.0
2.4
3.06
2.89
g/l
1.34
155
1692
6
41
1.46
0.50
1.0
1.0
—
—
—
0
0
354
3738
0.94
0.50
2.0
2.2
0.20
0.19
g/l
1.09
323
3439
79
892
0.88
0.49
3.5
1.3
59.13
43.48
u/l
0.50
71
767
104
1155
0.90
0.49
1.5
1.6
—
—
—
0
0
7
45
1.56
0.49
1.1
1.7
—
—
—
0
0
84
943
0.89
0.48
1.8
3.4
9067.49
779.39
u/ml
0.45
73
877
12
166
0.72
0.47
1.1
1.1
309.00
316.07
u/l
0.02
12
154
52
447
1.17
0.47
2.1
3.3
—
—
—
0
0
94
843
1.12
0.47
1.3
1.4
—
—
—
0
0
174
1879
0.92
0.47
2.3
3.3
47.34
65.87
mg/l
2.63
147
1583
174
1876
0.92
0.46
2.3
3.3
42.44
61.98
mg/l
1.16
148
1586
24
192
1.25
0.44
1.1
2.3
40.67
64.31
mg/l
1.77
15
140
126
1153
1.10
0.44
3.3
3.6
4.35
4.27
pmol/l
0.36
117
1004
7
51
1.37
0.44
1.0
1.2
—
—
—
0
0
60
682
0.88
0.43
1.7
1.6
—
—
—
0
0
20
157
1.28
0.43
1.2
2.1
—
—
—
0
0
14
185
0.76
0.43
3.4
1.7
37.48
39.22
g/l
0.51
14
185
30
360
0.83
0.42
1.5
1.6
30.00
30.51
u/ml
—
6
70
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
47.18
—
0
15
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
36.58
—
0
6
223
2099
1.07
0.40
1.2
1.2
—
—
—
0
0
273
2880
0.94
0.40
2.9
3.8
1.84
1.77
mmol/l
0.11
185
2047
7
105
0.67
0.39
1.7
1.8
—
—
—
0
0
24
196
1.23
0.39
1.1
1.2
85.96
90.15
pmol/l
0.19
24
196
24
291
0.82
0.38
1.2
1.3
—
72.27
—
0
22
45
392
1.15
0.37
1.4
1.5
—
—
—
0
0
12
158
0.76
0.37
1.1
1.1
—
—
—
0
0
184
1728
1.07
0.37
2.3
2.1
0.00
0.63
estimate
0.53
40
416
80
725
1.11
0.36
1.2
1.4
—
—
—
0
0
128
1187
1.08
0.36
1.2
1.5
—
—
—
0
0
50
441
1.14
0.35
1.3
1.6
8.28
3.72
iu/l
0.65
17
135
501
5186
0.96
0.35
5.7
7.6
94.91
95.06
%
0.16
477
5005
5
78
0.64
0.35
2.2
1.3
—
—
—
0
0
45
394
1.14
0.35
1.2
1.7
—
—
—
0
0
25
208
1.20
0.35
1.3
1.4
64.84
153.16
pmol/l
3.65
25
208
320
3344
0.95
0.35
3.0
4.1
4.96
5.11
kpa
2.10
299
3166
92
1003
0.92
0.34
1.3
1.5
270.64
246.12
ug/g
0.54
54
658
11
145
0.76
0.34
1.1
1.2
—
—
—
0
0
12
91
1.32
0.33
1.1
1.2
—
—
—
0
0
12
91
1.32
0.33
1.1
1.1
—
—
—
0
0
194
2052
0.94
0.33
1.9
2.4
4.11
4.10
g/l
0.04
174
1852
194
2051
0.94
0.33
1.9
2.4
7.64
7.31
g/l
1.60
174
1844
6
88
0.68
0.33
2.3
2.2
6.28
8.23
mmol/l
—
6
59
10
132
0.76
0.32
1.0
1.5
7.09
15.48
ug/l
—
10
119
450
4655
0.96
0.32
6.2
8.3
114.77
120.90
g/l
8.32
438
4554
74
811
0.91
0.32
1.4
1.5
1256.36
3282.53
e6/l
1.08
50
569
15
119
1.26
0.31
1.3
1.2
—
—
—
0
0
46
408
1.13
0.31
1.2
1.7
—
—
—
0
0
194
2046
0.95
0.31
1.9
2.4
3.81
3.78
g/l
0.07
174
1840
19
156
1.22
0.31
1.2
2.1
—
—
—
0
0
19
156
1.22
0.31
1.2
2.1
—
—
—
0
0
10
131
0.76
0.30
1.1
1.2
6.58
6.41
mmol/l
—
10
123
7
54
1.30
0.30
1.7
1.2
63.99
46.47
mg/l
—
7
48
7
57
1.23
0.29
2.7
1.2
6.29
15.75
mm/h
—
7
57
21
176
1.19
0.28
1.0
1.1
—
—
—
0
0
22
259
0.85
0.28
1.4
1.2
2.40
2.27
mmol/l
0.21
22
240
21
248
0.85
0.28
2.1
2.3
—
—
—
0
0
69
633
1.09
0.27
1.1
1.2
—
0.92
—
0
8
8
64
1.25
0.27
1.0
1.3
—
—
—
0
0
21
177
1.19
0.27
1.2
1.3
1.05
0.61
ratio
—
5
51
16
131
1.22
0.27
1.5
1.2
—
—
—
0
0
18
215
0.84
0.27
1.0
1.1
—
—
—
0
0
12
150
0.80
0.27
1.2
2.4
0.60
0.62
mmol/l
0.29
12
150
102
1090
0.93
0.26
1.9
2.2
3.77
3.48
ratio
1.28
84
912
40
357
1.12
0.26
1.2
1.7
—
—
—
0
0
40
357
1.12
0.26
1.2
1.7
—
—
—
0
0
40
357
1.12
0.26
1.2
1.7
—
—
—
0
0
78
842
0.92
0.26
1.1
1.1
—
—
—
0
0
12
149
0.80
0.25
1.0
1.1
—
—
—
0
0
48
434
1.11
0.25
1.2
1.4
—
—
—
0
0
19
224
0.85
0.25
1.6
1.8
125.21
104.74
umol/l
0.41
19
224
48
529
0.91
0.25
3.7
3.5
—
—
—
0
0
48
528
0.91
0.24
1.8
2.1
27.88
25.42
mg/l
0.10
17
174
9
77
1.17
0.24
1.0
1.1
—
—
—
0
0
559
5725
0.97
0.24
5.4
7.5
11.73
11.64
kpa
0.14
532
5485
19
161
1.18
0.24
1.5
1.4
6.47
1.74
u/ml
0.61
14
105
32
360
0.89
0.24
1.4
1.4
21.68
22.94
%
0.07
16
233
5
39
1.28
0.23
1.0
1.1
—
—
—
0
0
48
438
1.10
0.22
1.2
1.4
—
—
—
0
0
39
352
1.11
0.22
1.2
1.3
5.63
5.25
u/ml
0.03
19
124
560
5726
0.97
0.22
5.4
7.5
4.90
5.03
kpa
2.36
534
5489
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
5.6
—
—
—
0
0
99
934
1.06
0.21
1.2
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
6.6
—
—
—
0
0
11
89
1.24
0.21
1.0
1.1
—
—
—
0
0
33
297
1.11
0.20
1.1
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
53
573
0.92
0.20
3.1
4.5
13.42
11.99
pmol/l
0.28
53
573
74
694
1.07
0.19
1.2
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
6
51
1.18
0.19
5.0
2.5
0.33
0.20
u/field
—
6
51
68
726
0.94
0.19
1.3
1.5
72992.03
67913.58
e6/l
0.06
38
424
42
385
1.09
0.19
3.4
1.3
218.78
252.89
pmol/l
0.51
36
305
64
601
1.07
0.17
8.2
19.9
7.76
7.50
mmol/l
0.20
54
491
48
446
1.08
0.17
1.2
1.4
—
—
—
0
0
5
70
0.71
0.16
1.0
1.2
—
—
—
0
0
84
797
1.06
0.16
1.3
1.2
—
—
—
0
0
24
215
1.12
0.16
1.1
1.3
1.37
1.41
g/l
0.34
24
215
73
690
1.06
0.16
1.2
1.2
—
—
—
0
0
8
70
1.14
0.16
1.0
1.1
—
—
—
0
0
23
206
1.12
0.16
1.3
1.5
—
—
—
0
0
23
206
1.12
0.16
1.3
1.5
—
—
—
0
0
6
79
0.76
0.15
1.0
1.4
—
—
—
0
0
9
81
1.11
0.15
1.0
1.1
—
—
—
0
0
2813
28014
1.01
0.15
5.2
6.0
6.23
6.25
mmol/l
0.28
2510
24979
1168
11795
0.99
0.14
2.4
2.3
250.93
249.94
u/l
0.01
1101
11105
7
86
0.81
0.14
2.0
2.1
—
—
—
0
0
7
87
0.80
0.14
2.0
2.1
—
—
—
0
0
11
93
1.18
0.14
1.1
1.3
1.13
1.17
mmol/l
0.97
11
93
297
3038
0.98
0.14
4.4
6.9
23.83
24.23
mmol/l
0.89
280
2917
25
227
1.10
0.14
1.0
1.1
—
—
—
0
0
271
2648
1.03
0.14
2.6
2.5
387.11
380.40
nmol/l
0.17
256
2440
172
1770
0.97
0.13
1.6
2.4
9.75
10.50
g/l
1.80
146
1547
815
8059
1.01
0.13
2.0
1.8
24559228.96
31307674.51
pmol/l
0.14
680
6548
136
1402
0.97
0.12
1.7
2.4
0.00
0.00
g/l
1.04
115
1202
21
230
0.91
0.11
1.1
1.2
—
—
—
0
0
558
5652
0.99
0.11
5.4
7.5
0.43
0.79
mmol/l
1.07
423
4552
50
474
1.06
0.11
1.2
1.4
148.82
159.07
au/ml
0.18
11
141
19
209
0.91
0.11
2.0
2.2
155.32
143.10
ng/l
0.16
19
209
128
1319
0.97
0.11
1.4
1.7
—
—
—
0
0
23
211
1.09
0.11
2.1
1.8
—
—
—
0
0
801
8084
0.99
0.10
1.9
1.8
1102.88
1131.12
nmol/l
0.39
618
6077
32
300
1.07
0.10
1.3
1.5
—
—
—
0
0
15
135
1.11
0.09
1.1
1.1
0.23
1.05
u/ml
—
10
78
32
340
0.94
0.09
1.3
1.2
4.80
5.88
u/ml
0.20
15
159
1675
16669
1.01
0.09
2.2
2.4
89.59
90.59
pmol/l
0.41
1021
9851
2275
22671
1.01
0.08
3.9
4.5
19.25
14.49
mm/h
20.39
2077
20890
5
60
0.83
0.08
1.0
1.1
—
—
—
0
0
43
450
0.96
0.08
1.1
1.2
305.38
288.41
u/ml
0.17
26
270
22
205
1.07
0.07
2.5
2.7
33.09
33.77
%
0.04
11
121
8
75
1.07
0.07
1.0
1.1
—
—
—
0
0
274
2777
0.99
0.07
7.2
9.9
15.49
15.97
%
2.11
262
2683
33
346
0.95
0.06
1.9
1.3
0.28
0.19
nmol/l
—
6
29
27
285
0.95
0.06
2.1
1.2
0.19
0.20
nmol/l
0.30
21
246
66
680
0.97
0.06
1.2
1.3
—
—
—
0
0
44
423
1.04
0.06
1.2
1.5
—
—
—
0
0
21
197
1.07
0.06
2.4
2.1
—
—
—
0
0
14
152
0.92
0.06
2.1
1.2
—
—
—
0
0
293
2963
0.99
0.06
6.9
9.1
23.71
24.06
mmol/l
1.07
286
2872
44
456
0.96
0.05
1.3
1.4
66.78
66.91
%
0.01
27
291
17
182
0.93
0.05
1.1
1.2
—
84.37
—
0
16
14
129
1.09
0.05
1.0
1.1
—
—
—
0
0
16
149
1.07
0.05
1.2
1.2
—
—
—
0
0
16
149
1.07
0.05
1.2
1.2
—
—
—
0
0
49
505
0.97
0.05
1.1
1.2
—
125.48
—
0
5
44
426
1.03
0.05
1.2
1.4
—
—
—
0
0
44
426
1.03
0.05
1.2
1.4
—
—
—
0
0
11
101
1.09
0.04
1.1
1.1
—
—
—
0
0
18
170
1.06
0.04
1.1
1.0
—
—
—
0
0
37
382
0.97
0.04
1.3
1.3
276.38
278.20
mosm/kgh2o
0.18
26
285
129
1306
0.99
0.03
1.7
2.5
0.00
0.00
g/l
-0.00
114
1197
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
141
1.06
0.03
1.1
1.1
—
—
—
0
0
266
2676
0.99
0.02
3.2
4.6
108.12
110.71
ng/l
0.15
235
2301
21
218
0.96
0.02
1.7
2.1
18.10
17.30
%
0.11
21
211
10
107
0.93
0.02
5.2
8.2
4.70
5.53
kpa
—
10
107
145
1460
0.99
0.01
1.8
2.4
0.01
0.04
g/l
1.90
127
1288
2762
27635
1.00
0.01
7.1
7.9
40.72
41.26
mmol/mol
2.49
2527
25221
16
154
1.04
0.00
1.1
1.1
—
—
—
0
0
22
226
0.97
0.00
1.9
2.1
—
—
—
0
0
34
334
1.02
0.00
2.2
2.0
8.32
7.84
mmol/l
0.43
34
334
10
102
0.98
0.00
2.4
2.1
36.60
31.82
%
—
10
95
29
292
0.99
0.00
1.3
1.5
—
—
—
0
0
90
898
1.00
0.00
1.6
1.5
—
—
—
0
0
26
261
1.00
0.00
1.2
1.2
7.61
7.90
mmol/l
0.21
20
220
38
381
1.00
0.00
1.7
2.2
841.91
653.88
ml
1.24
23
232
34
336
1.01
0.00
1.3
1.4
—
—
—
0
0
42
423
0.99
0.00
1.0
1.1
1.00
421.82
iu/ml
—
5
87
13
127
1.02
0.00
1.3
1.1
170.85
250.02
iu/ml
0.63
13
127
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
8.22
—
0
5
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
3.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
2.86
—
0
9
0
7
0.00
-0.00
0.0
3.7
—
30.86
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
1465.88
—
0
8
0
6
0.00
-0.00
0.0
3.3
—
2.85
—
0
6
8
84
0.95
-0.00
3.4
1.5
308.75
222.24
%
—
8
79
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
6
65
0.92
-0.00
1.2
1.2
—
—
—
0
0
8
86
0.93
-0.00
6.3
7.7
8.76
10.22
%
—
8
86
9
95
0.95
-0.00
1.3
1.9
37.04
20.28
ug/l
—
9
89
29
290
1.00
-0.00
1.1
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
8
83
0.96
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
1.17
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BB – L02BB Anti-androgens
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).